Asa Abeliovich

Company: Leal Therapeutics

Job title: Chief Executive Officer & Founder

Seminars:

Degrading SPTLC1 RNA to Reduce Lipid Production in ALS with LTX-002 ASO 1:30 pm

Translating ASO potency in mice to CNS target engagement with repeat IT dosing target engagement in rodents with repeat IT dosing in patients Reviewing NfL reduction as a surrogate endpoint at 3 months for 12 months sustained reduction Establishing SPTLC1 ASO LTX-002 for safety, target engagement and biodistribution to critical CNS regions in NHP brainsRead more

day: Conference Day Two